|1.||Gao, Xiaoling: 8 articles (12/2015 - 01/2013)|
|2.||Chen, Jun: 8 articles (12/2015 - 01/2013)|
|3.||Kang, Ting: 7 articles (12/2015 - 01/2013)|
|4.||Song, Qingxiang: 7 articles (08/2015 - 01/2013)|
|5.||Jiang, Xinguo: 6 articles (12/2015 - 01/2013)|
|6.||Hu, Quanyin: 6 articles (09/2014 - 01/2013)|
|7.||Pang, Zhiqing: 5 articles (11/2015 - 01/2013)|
|8.||Gu, Guangzhi: 5 articles (09/2014 - 01/2013)|
|9.||Chen, Hongzhuan: 5 articles (09/2014 - 06/2013)|
|10.||Yao, Lei: 5 articles (03/2014 - 01/2013)|
08/25/2014 - "In the efficacy study with MCF-7 tumor bearing mice, PEG-PTX/PTX showed significantly higher antitumor activity than PEG-PLA/PTX at the same PTX dosage. "
01/15/2015 - "These results demonstrate that the in vitro and in vivo metabolic and anti-tumor effects of RSV is preserved by PEG-PLA NP loading, and provide an encouraging outlook on the potential of polymeric NPs as an effective method to deliver RSV for cancer therapy. "
01/01/2015 - "The concentrated OP-PEG-PLA NPs are good in clinical application and tumor delivery. "
01/01/2015 - "Compared to OP-PLA NPs groups, OP concentration of OP-PEG-PLA NPs groups increased in the tumor and decreased in the liver and lung (p < 0.05). "
11/22/2011 - "Tumor accumulation of NIR fluorescent PEG-PLA nanoparticles: impact of particle size and human xenograft tumor model."
09/01/2014 - "PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy."
10/15/2013 - "The cell viability of Tf-PEG-PLA-RSV on C6 and U87 glioma cells was determined by the MTT assay. "
09/01/2010 - "The flow cytometer measurement demonstrated the targeting ability of the nanoparticles to tumor cells in vitro, and the fluorescence microscopy observation of brain sections from C6 glioma tumor-bearing rat model gave the intuitive proof that Tf functionalized PEG-PLA nanoparticles could penetrate into tumor in vivo."
10/15/2013 - "In vitro cytotoxicity of PEG-PLA-RSV against C6 and U87 cells was higher than that of free RSV, and further the modification of Tf enhanced the cytotoxicity of the RSV-polymer conjugates as a result of the increased cellular uptake of the RSV-modified conjugates by glioma cells. "
01/01/2013 - "F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery."
|3.||Glioblastoma (Glioblastoma Multiforme)
08/19/2015 - "Mammary-Derived Growth Inhibitor Targeting Peptide-Modified PEG-PLA Nanoparticles for Enhanced Targeted Glioblastoma Therapy."
04/02/2010 - "Therefore, our results suggested that c(RGDyK)-PEG-PLA micelle may be a potential drug delivery system in the treatment of integrin alpha(v)beta(3) over-expressed glioblastoma."
04/02/2010 - "In U87MG glioblastoma-bearing nude mice model, biodistribution of (125)I-radiolabeled c(RGDyK)-PEG-PLA or DiR encapsulated micelles and anti-glioblastoma pharmacological effect was investigated after intravenous administration. "
07/01/2013 - "In this study, MT1-AF7p peptide, which presents high binding affinity to membrane type-1 matrix metalloproteinase (MT1-MMP) that over-expressed on both angiogenic blood vessels and glioma cells, was employed to decorate the paclitaxel-loaded PEG-PLA nanoparticles (MT1-NP-PTX) to mediate glioblastoma targeting. "
06/28/2012 - "While at the same dosages, the median survival of the intracranial glioblastoma-bearing model mice treated with co-delivery (33.5 days) is significantly longer than those of solely treated mice with CDX-PEG-PLA-PTX (25.5 days), RGD-PEG-PEI/pORF-hTRAIL (24.5 days) or physiological saline (21.5 days). "
|4.||Breast Neoplasms (Breast Cancer)
11/01/2014 - "These results suggest that ScFvHer2 -decorated PEG-PLA-based nanoparticles show great potential for targeted RNA interference therapy of Her2(+) breast tumor."
11/01/2014 - "In this study, for targeted delivery of siPlk1 to Her2(+) breast cancer, anti-Her2 single-chain variable fragment antibody (ScFv(Her2))-decorated PEG-PLA-based nanoparticles with si Plk1 encapsulation (ScFv(Her2)-NP(si) Plk1) are developed. "
11/01/2014 - "ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer."
10/28/2014 - "Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles."
11/01/2014 - "Dose-dependent anti-tumor efficacy further demonstrates that ScFvHer2 -decorated PEG-PLA-based nanoparticles with siPlk1 encapsulation can significantly enhance the inhibition of Her2(+) breast tumor growth and reduce the dose of injected siRNA. "
01/01/2014 - "Local delivery of minocycline-loaded PEG-PLA nanoparticles for the enhanced treatment of periodontitis in dogs."
11/15/2015 - "In this study, a novel epithelial cell-targeting nanoparticle drug delivery system by conjugating minocycline-loaded poly(ethylene glycol)-poly(lactic acid) (PEG-PLA) nanoparticles (NP-MIN) with RGD peptide were developed and administrated locally for targeting periodontitis epithelial cells and enhancing the treatment of periodontitis in dogs. "
|1.||poly(lactic acid) (polylactic acid)
|2.||Polyethylene Glycols (Polyethylene Glycol)
|6.||Ethylene Glycol (Monoethylene Glycol)
|10.||Transferrin (beta 2 Transferrin)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)